Table 1.
Subject characteristics
| Patients (n=11) |
Controls (n=11) |
p Value | |
| Age (years) | 68 (6.1) | 67 (9.0) | 0.67 |
| Height (cm) | 174 (5.5) | 177 (8.5) | 0.22 |
| Weight (kg) | 80.6 (15.9) | 83.4 (8.8) | 0.62 |
| LVEDD (cm) | 6.9 (0.7) | 5.0 (0.7) | <0.0001 |
| LVEF (%) | 31.8 (2.9) | 56.7 (10.4) | <0.0001 |
| Drugs | |||
| Furosemide* | 83.4 (53.4) | ||
| ACEi/AIIA (n) | 23 | ||
| Spironolactone (n) | 5 | ||
| New York Heart Association functional class (n) | |||
| I | 0 | ||
| II | 4 | ||
| III | 7 | ||
| IV | 0 | ||
| PV̇o2 (ml/kg/min) | 20.7 (4.9) | 37.6 (9.6) | <0.0001 |
| Exercise time (s) | 471 (226) | 855 (225) | 0.0007 |
| RER | 1.06 (0.06) | 1.08 (0.08) | 0.50 |
| HR/O2 slope | 4.25 (1.4) | 2.92 (0.7) | 0.01 |
| AT | 15.5 (4.8) | 27.0 (7.4) | 0.0003 |
| VE/V̇co2 slope | 37.1 (8.2) | 26.5 (4.1) | 0.0011 |
| VE peak (l/min) | 64.5 (13.5) | 97.4 (21.3) | 0.0003 |
| Borg/VE slope | 0.28 (0.39) | 0.12 (0.05) | 0.017 |
Values are means (SD).
*Mean (SD) daily dose of furosemide (frusemide).
ACEi, angiotensin converting enzyme inhibitor; AIIA, angiotensin II inhibitor; AT, anaerobic threshold;
HR, heart rate; LVEDD, left ventricular end diastolic dimension form M mode echocardiography; LVEF, left ventricular ejection fraction; PV̇o2, peak oxygen consumption; RER, respiratory exchange ratio (V̇co2/V̇o2); VE, minute ventilation.